Toggle navigation
About
About The ASCO Post
Editorial Board
Rights and Permissions
Contact
Subscribe
News
FDA Update
Journal Spotlight
Expert's Corner
In the Clinic
View By Issue
View All
Meetings
2024 SABCS
Thematic Newsreels
2024 ASH Annual Meeting
RSNA 2024 Annual Meeting
2024 JADPRO Live
Calendar
View All
Topics
Breast Cancer
Lung Cancer
Prostate Cancer
Lymphoma
Cardio-oncology
View All
Videos
Newsreels
Video Roundtables
Podcasts
Subscribe
Advertisement
The ASCO Post Newsreels help clinicians stay up to date on news in the world of clinical oncology and hematology. Newsreels feature leading authorities presenting high-impact clinical findings at major oncology meetings throughout the year.
Showing All Recent Newsreels Videos
Select Meeting
Toggle Dropdown
2021 ASCO Annual Meeting
AACR Annual Meeting 2021
SGO 2021 Virtual Annual Meeting on Womens Cancer
NCCN 2021 Virtual Annual Conference
Quick Chats
View all
Advertisement
2024 SABCS
Sibylle Loibl, MD, PhD, on Primary Results of the Randomized, Phase III PADMA Study in HER2-Negative/HR-Positive Metastatic Breast Cancer
Mafalda Oliveira, MD, PhD, on Primary Results of SOLTI VALENTINE
Aditya Bardia, MD, on Destiny-Breast06: An Additional Analysis
Adrienne Waks, MD, on MARGOT/TBCRC052: Phase II Trial in HER2-Positive Breast Cancer
Nan Chen, MD, on Impact of Anthracyclines in High Genomic Risk Node-Negative HR-Positive/HER2-Negative Breast Cancer
Andrew Tutt, MB ChB, PhD, FMedSci, on OlympiA: High-Risk BRCA-Positive Breast Cancer
2024 JADPRO Live
Justin Arnall, PharmD, BCOP, FCCP, on Complicating “Factors”: When Malignancy and Non-Malignant Hematology Collide
Kathryn Newlin, RN, MSN, ANP-BC, on Updates in HR-Positive, HER2-Negative Metastatic Breast Cancer
Cara Norelli, MS, AGNP-C, on Managing Dermatologic Side Effects in Patients With Cancer
Thematic Newsreels
Ovarian Cancer 2024: Year at a Glance, Part 1
Ovarian Cancer 2024: Year-at-a-Glance, Part 2
Allison Betof Warner, MD, PhD, on TIL Therapy for Advanced Melanoma: Innovative Clinical Advances in Treatment
2024 ASH Annual Meeting
Nikolaos Katsivelos, MD, and John Levine, MD, MS, on How Serial Clinical and Biomarker Monitoring During Treatment Can Stratify Patients With Low-Risk GVHD
Maayan Levy, PhD, and Marco Ruella, MD, on How a Ketogenic Diet Enhances CAR T-Cell Antitumor Function Via Beta-Hydroxybutyrate (BHB)
Jennifer R. Brown, MD, PhD, on Fixed-Duration Acalabrutinib/Venetoclax in Fit Patients With CLL: AMPLIFY Trial
Anne Sophie Michallet, MD, PhD, on MRD-Guided vs Standard Combination Therapy for Select Untreated Patients With CLL
Danielle Wolfe Cohen, MD, on Mechanisms of Relapse in B-Cell Acute Lymphoblastic Leukemia
Nitin Jain, MD, on First-Line Treatment With Pirtobrutinib-Based Regimen in CLL
Rachel E. Rau, MD, and Sumit Gupta, MD, PhD, on Pediatric B-Cell ALL: Blinatumomab Added to Chemotherapy in Newly Diagnosed Disease
Timothy S. Fenske, MD, on Lack of Benefit of Autologous Hematopoietic Cell Transplantation in Mantle Cell Lymphoma Patients in First Complete Remission With Undetectable Minimal Residual Disease
John O. Mascarenhas, MD, on Relapsed/Refractory Myelofibrosis: Navtemadlin vs Best Available Therapy After JAK Inhibitor Treatment
John O. Mascarenhas, MD, on Myelofibrosis: Novel Combination of Imetelstat Plus Ruxolitinib
Matthew S. Davids, MD, MMSc, on Triplet Therapy of Acalabrutinib, Venetoclax, and Obinutuzumab: Focus on TP53-Aberrant CLL
Jenny Paredes, PhD, on How Increased Fiber Intake Results in Better Overall Survival and Lower GI-aGVHD in Allo-HCT Recipients and Pre-Clinical GVHD Models
Natalie Wuliji, DO, and Mohamed Sorror, MD, MSc, on the Impact of Socioeconomic Factors on Access to and Outcomes of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: A Multi-Center Observational Study
Hannah Choe, MD, on Dynamics of Overall and Organ-Specific Responses to Axatilimab in Chronic Graft-Versus-Host Disease: Analysis from the AGAVE-201 Study
Erik Thiele Orberg, MD, PhD, on Recovery of the Intestinal Microbiome in Patients at Day +100 after Allogeneic Stem Cell Transplantation Is Defined by Microbial Metabolite Profiles and Linked to Long-Term Outcomes
42nd Annual Chemotherapy Foundation Symposium
Vered Stearns, MD, on Shifting Patient Outcomes: Updates in Triple-Negative Breast Cancer
Komal Jhaveri, MD, FACP, on Antibody-Drug Conjugates in Breast Cancer
Tiffany Traina, MD, FASCO, on Advances in the Treatment of HR-Positive Breast Cancer
Lynn Sage Breast Cancer Symposium 2024
Frederick Howard, MD, on the Role of Targeted Therapy and Endocrine Therapy in the Patient With Breast Cancer
Charles E. Geyer, Jr, MD, FACP, on Management of the Patient With HER2-Positive Breast Cancer in 2024
Sunil S. Badve, MD, FRCPath, on Tumor-Infiltrating Lymphocytes in the Patient With Breast Cancer
William Gradishar, MD, on Advances in Endocrine Therapeutic Options for Patients With ER-Positive, HER2-Negative Breast Cancer
Timely Topics
Julie Gralow, MD, FACP, FASCO, on Conserving IV Fluid Supplies During Natural Disasters
ESMO Congress 2024
Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Unresectable Hepatocellular Carcinoma: 5-Year Overall Survival Results From the HIMALAYA Trial
Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Doublet Immunotherapy Options for Unresectable Hepatocellular Carcinoma
Josep M. Llovet, MD, PhD, on Intermediate-Stage Hepatocellular Carcinoma: Addition of Lenvatinib Plus Pembrolizumab to TACE
Josep M. Llovet, MD, PhD, on Treatment Options in Hepatocellular Carcinoma
Rachna T. Shroff, MD, MS, FASCO, on Advanced Hepatocellular Carcinoma: Anlotinib Plus Penpulimab vs Sorafenib
Maeve Lowery, MD, on a Novel Bifunctional Antibody in Advanced Hepatocellular Carcinoma
IBC East 2024
Paolo Tarantino, MD, on the Current and Future Landscape of Antibody-Drug Conjugates
Joseph A. Sparano, MD, FACP, on Premenopausal HR-positive Early Breast Cancer: What to Do Outside the OFSET Trial?
Kristin Rojas, MD, FACS, on Improving Sexual Health During Breast Cancer Treatment
IBC West 2024
Aditya Bardia, MD, MPH, FASCO, on the Current and Future Landscape of Antibody-Drug Conjugates
Heather McArthur, MD, MPH, on Immunotherapy for High-Risk, Early-Stage Breast Cancer
Aditya Bardia, MD, MPH, FASCO, on Novel Therapies Targeting the Estrogen Receptor
Sara A. Hurvitz, MD, FACP, on New Therapeutic Strategies for HER2-Positive Metastatic Disease Including Brain Metastases
2024 ASCO Annual Meeting
Muhit Özcan, MD, on CLL/SLL: Report on a Still-Recruiting International Study of Nemtabrutinib, Venetoclax, and Rituximab
Toni K. Choueiri, MD, FASCO, on RCC: Biomarker Analysis From the CLEAR Trial
Xavier P. Leleu, MD, PhD, on Multiple Myeloma: Update on Isatuximab, Lenalidomide, Dexamethasone, and Bortezomib
Tomasz Jankowski, MD, PhD, on Non–Small Cell Lung Cancer: New Data on a Telomere-Targeting Agent
Fabrice Andre, MD, PhD, on Breast Cancer: Interim Analysis From DESTINY-Breast07
Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel
Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Update on BTK Inhibitors
Mazyar Shadman, MD, MPH, on Chronic Lymphocytic Leukemia: Recruiting for the CELESTIAL-TNCLL Study
Ana C. Garrido-Castro, MD, on Metastatic Breast Cancer: Trial Update on Sacituzumab Govitecan With or Without Pembrolizumab
Ana C. Garrido-Castro, MD, on Managing Metastatic Breast Cancer in 2024
Denise A. Yardley, MD, on Early Breast Cancer: Findings From the NATALEE Trial on Patients With Node-Negative Disease
Anthony M. Joshua, MBBS, PhD, on Low-Risk Prostate Cancer and Metformin: New Trial Data
Lisa A. Carey, MD, and Kevin Kalinsky, MD, on Advanced Breast Cancer: New Data on Abemaciclib and Fulvestrant From the postMONARCH Trial
Jens Marquardt, MD, and Jens Hoeppner, MD, on Esophageal Cancer: Phase III Findings on Chemotherapy vs Chemoradiation
Lisa A. Carey, MD, and Dejan Juric, MD, on Breast Cancer: Updates From the INAVO120 Trial
Christian U. Blank, MD, PhD, on Melanoma: Potentially Practice-Changing Results From the NADINA Trial
Don S. Dizon, MD, on Ovarian and Other Extrarenal Clear Cell Carcinomas: Update on Nivolumab and Ipilimumab
Joseph A. Greer, PhD, on Lung Cancer: Telehealth vs In-Person Palliative Care
Reshma Jagsi, MD, and Christian F. Singer, MD, MPH, on Early-Stage Breast Cancer: Adding a Vaccine to Neoadjuvant Systemic Therapy
Belinda Lee, MBBS, on Early-Stage Pancreatic Cancer: New Data on Guiding Adjuvant Chemotherapy
Clifford A. Hudis, MD: A Message From ASCO’s CEO
Clifford A. Hudis, MD, and Karen E. Knudsen, MBA: An ASCO–American Cancer Society Partnership to Benefit Patients
Pauline Funchain, MD, and Caroline Robert, MD, PhD, on Melanoma: New Data on Encorafenib, Binimetinib, Ipilimumab, and Nivolumab
Pauline Funchain, MD and Paolo A. Ascierto, MD, on Advanced Melanoma: Results From the RELATIVITY-048 Trial
Alicia Morgans, MD, MPH, and Susan Halabi, PhD, on Prostate Cancer: New Findings on Classifying Patients Into Risk Groups
David J. Andorsky, MD, on DLBCL and FL: New Data on Use of Subcutaneous Epcoritamab
Jean-Marc Classe, MD, PhD, on Ovarian Cancer: New Data on Lymphadenectomy From the CARACO Trial
Suzanne Trudel, MD, on Multiple Myeloma: Results From the DREAMM-8 Study of Treatments After Relapse
Luciano J. Costa, MD, PhD, on Multiple Myeloma: Subgroup Analysis of CARTITUDE-4 on Ciltacabtagene Autoleucel
Eva M. Ciruelos, MD, PhD, on HER2-Positive and PAM50 Luminal Breast Cancer: Primary Results From the PATRICIA Trial
Mostafa Eyada, MD, on Oral Cyclophosphamide Plus Bevacizumab in Recurrent Ovarian Cancer
Axel Hauschild, MD, on Melanoma: Findings From the PIVOTAL Trial of Daromun vs Surgery
Yucai Wang, MD, PhD, on Richter Transformation of CLL: Findings on Combination Therapy With an Immune Checkpoint Inhibitor
Emily L. Podany, MD, on Metastatic Breast Cancer: Racial Differences in Genomic Profiles and Targeted Treatment Use
Peter Riedell, MD, on DLBCL: Expert Commentary on the DEB Study
Thierry Facon, MD, on Multiple Myeloma: Results From the IMROZ Study on Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone
Peter Riedell, MD, on DLBCL: Expert Commentary on Data From the ECHELON-3 Study
Allison M. Winter, MD, on Richter Transformation: New Data on a CAR T-Cell Treatment
Joshua D. Brody, MD, on Follicular Lymphoma: New Data on Epcoritamab, Rituximab, and Lenalidomide
Sherene Loi, MD, PhD, on Early-Stage Breast Cancer: Weighing the Prognostic Value of ctDNA Detection
Pierfranco Conte, MD, on Early-Stage Triple-Negative Breast Cancer: Trial Update on Avelumab as Adjuvant Treatment
Reshma Jagsi, MD, DPhil, and Tarah J. Ballinger, MD, on Early-Stage Breast Cancer in Black Women: Docetaxel and Peripheral Neuropathy
Heather Wakelee, MD, on NSCLC: IMpower010 Survival Results After Long-Term Follow-up of Atezolizumab vs Best Supportive Care
Tony S.K. Mok, MD, on NSCLC: Adagrasib vs Docetaxel in KRAS G12C–Mutated Disease
Alex Andrea Francoeur, MD, on Endometrial Cancer and Obesity Trends
Brian I. Rini, MD, on Renal Cell Carcinoma: Exploratory Biomarker Results
Narjust Florez, MD, and David R. Spigel, MD, on Limited-Stage Small Cell Lung Cancer: Results From the ADRIATIC Study
Christos Kyriakopoulos, MD, on Prostate Cancer: CHAARTED2 Trial Results on Cabazitaxel and Abiraterone
Omid Hamid, MD, on Cutaneous Melanoma: Update on a Bispecific Protein Under Study
Thomas Powles, MD, PhD, and Jonathan E. Rosenberg, MD, on Urothelial Carcinoma: The DESTINY-Pan Tumor02 Study and New Findings on Sacituzumab Govitecan
Minesh P. Mehta, MD, on NSCLC: Tumor Treating Fields for Brain Metastases
Jonathan E. Rosenberg, MD, and Thomas Powles, MD, PhD, on Urothelial Carcinoma: Expert Commentary on Two Key Abstracts
Narjust Florez, MD, and Suresh S. Ramalingam, MD, on EGFR-Mutated NSCLC: Update on Osimertinib and Chemoradiotherapy
Jeanne Tie, MD, MBChB, on Colon Cancer: New Data on ctDNA Guiding Adjuvant Therapy
Efrat Dotan, MD, on Pancreatic Cancer in Older Adults: Defining the Optimal Treatment Approach
Yeon Hee Park, MD, PhD, on Metastatic Breast Cancer: Updated Survival Results of the Young-PEARL Study
Laurence Albiges, MD, PhD, on Renal Cell Carcinoma: Biomarker Analysis of the IMmotion010 Study
Alicia Morgans, MD, MPH, and Karim Fizazi, MD, PhD, on Prostate Cancer: Study Findings on Health-Related Quality of Life and Pain
Yukio Suzuki, MD, PhD, on Endometrial Cancer: Long-Term Survival Outcomes With Hormonal Therapy in Reproductive-Age Patients
William G. Wierda, MD, PhD, on CLL/SLL: Updated Findings on Ibrutinib and Venetoclax
Amrita Y. Krishnan, MD, and Paula Rodríguez-Otero, MD, PhD, on Multiple Myeloma: Findings From the PERSEUS Trial on a Regimen for Transplant-Eligible Patients
Paula Rodríguez-Otero, MD, PhD, and Amrita Y. Krishnan, MD, on Multiple Myeloma: Moving BCMA-Directed Therapies to Earlier Use
Alicia Morgans, MD, MPH, and Samuel R. Denmeade, MD, on Prostate Cancer: Results From the TRANSFORMER Trial
Yasmin H. Karimi, MD, on Diffuse Large B-Cell Lymphoma: Update on Use of Epcoritamab Plus Chemotherapy
Yasmin H. Karimi, MD, on Large B-Cell Lymphoma: Follow-up on Subcutaneous Epcoritamab Monotherapy
Georgina V. Long, MD, PhD, on BRAF-Mutated Melanoma: Long-Term Follow-up of Adjuvant Dabrafenib Plus Trametinib vs Placebo
Andrea Cercek, MD, on Rectal Cancer: Durable Complete Responses to PD-1 Blockade Alone
Andrew Srisuwananukorn, MD, and Alexander T. Pearson, MD, PhD, on Artificial Intelligence in the Clinic: Understanding How to Use This 21st Century Tool
Claudio Cerchione, MD, PhD, on Staging Multiple Myeloma: New Findings on FDG PET/CT Scans and Whole-Body MRI
Ciara C. O’Sullivan, MD, MBBCh, on HER2-Positive Breast Cancer: Expert Commentary on Treatments Under Study
Milana Bergamino Sirvén, MD, PhD, on HER2-Positive Early-Stage Breast Cancer: Molecular Profiling, Prognosis, and Treatment Options
2024 NCCN Annual Conference
William J. Gradishar, MD, on HR-Positive, HER2-Negative Breast Cancer: Management Update
Natalie S. Callander, MD, on Multiple Myeloma: Management Updates
Wendy Vogel, MSN, FNP, AOCNP, FAPO, on the Evolving Role of Advanced Practice Providers in Oncology Care
Douglas B. Johnson, MD, MSCI, on Cutaneous Melanoma: Treatment Updates
AACR Annual Meeting 2024
Kelly K. Hunt, MD, on Breast Cancer and Neoadjuvant Therapy: Expert Commentary
Pasi A. Jänne, MD, PhD, on NSCLC, Osimertinib, Chemotherapy: Update From FLAURA2
2024 Society of Surgical Oncology Annual Meeting
Natália Polidorio, MD, PhD, on Triple-Negative Breast Cancer: Impact of Race on Treatment Efficacy
Heather McArthur, MD, MPH, on Early-Stage High-Risk ER+/HER2− Breast Cancer: New pCR Results for Pembrolizumab and Chemotherapy
Kerollos N. Wanis, MD, PhD, on Risks for BRCA Mutation Carriers Treated With Breast-Conserving Therapy
Akhil G. Pachimatla, MD, on NSCLC: A Link Between Image-Based Measures of Obesity and Metabolic Pathways
Judy C. Boughey, MD, on De-escalating Axillary Surgery After Chemotherapy for Breast Cancer
Jenny H. Chang, MD, on New Findings on Merkel Cell Carcinoma and Neoadjuvant Immunotherapy
Sophia McKinley, MD, EdM, on Cutaneous Melanoma: Outcomes With Adjuvant Immunotherapy
SGO 2024 Annual Meeting on Womens Cancer
Brian M. Slomovitz, MD, on Cervical Cancer: Update on Tisotumab Vedotin vs Chemotherapy
Mansoor R. Mirza, MD, on Endometrial Cancer: Update on Combination Regimen of Dostarlimab, Chemotherapy, and Niraparib
Mary McCormack, PhD, MBBS, on Locally Advanced Cervical Cancer: Results From the INTERLACE Trial
Anne Knisely, MD, on Ovarian Cancer and the Implications of Detecting Residual Disease and ctDNA
Matthew A. Powell, MD, on Endometrial Cancer: Overall Survival Update on Dostarlimab-gxly Plus Chemotherapy
Ana Oaknin, MD, PhD, on Recurrent Cervical Cancer: New Findings on Atezolizumab, Bevacizumab, and Chemotherapy
2024 Multidisciplinary Head and Neck Cancers Symposium
Nabil F. Saba, MD, on Head and Neck Cancer: Long-Term Survival Findings With Pembrolizumab and Cabozantinib
Christopher A. Barker, MD, on New Data on Vismodegib and Radiotherapy for Basal Cell Carcinoma of the Head and Neck
Nabil F. Saba, MD, on Preventing Radiation-Induced Mucositis in Patients With Squamous Cell Carcinoma of the Head and Neck
Pooja Karukonda, MD, on Coping With Financial Toxicity in Head and Neck Cancer
Evan M. Graboyes, MD, MPH, on Addressing Body Image Distress: Critical Care for Head and Neck Cancer Survivors
Evan M. Graboyes, MD, MPH, on Decreasing Delays in Adjuvant Therapy for Head and Neck Cancer
Eleni M. Rettig, MD, on HPV-Related Oropharyngeal Cancers: Early Detection and Disease Surveillance
Samuel Regan, MD, and Benjamin Rosen, PhD, on De-escalating Radiotherapy for HPV-Related Oropharyngeal Cancer
Dan P. Zandberg, MD, on Personalized Immunotherapy for HNSCC: Progress Report
Marcin R. Dzienis, MBBS, on Update on Pembrolizumab, Carboplatin, and Paclitaxel in HNSCC
2024 ASCO GU Cancers Symposium
Neeraj Agarwal, MD, on Prostate Cancer: Phase III Trial Update on Cabozantinib, Atezolizumab, and Hormonal Therapy
Maha H.A. Hussain, MD, on Prostate Cancer: New Data on Abiraterone and Prednisone Plus Olaparib
Amanda Nizam, MD, on Urothelial Carcinoma: Study Results on Enfortumab Vedotin and Avelumab
Thomas Powles, MD, on RCC: Patient-Reported Outcomes With Belzutifan vs Everolimus
Syed Muneeb Alam, MD, on Urothelial Carcinoma: Microsatellite Instability and Response to Immune Checkpoint Blockade
Umang Swami, MD, on Prostate Cancer: Differences in Genomic, Transcriptomic, and Immune Landscape Based on Site of Metastasis
Saby George, MD, on Clear Cell Kidney Cancer: Subcutaneous vs Intravenous Nivolumab
Michiel S. Van Der Heijden, MD, PhD, on Metastatic Urothelial Carcinoma: Phase III Trial Data on Enfortumab Vedotin Plus Pembrolizumab vs Chemotherapy
Enrique Grande, MD, on Adrenocortical Carcinoma: Phase II Results on Cabozantinib Plus Atezolizumab
David H. Aggen, MD, PhD, on Advanced Bladder Cancer: HER2 and PD-L1 Immunohistochemistry and HER2 Genomic Alterations
Andrew Johns, MD, on Clear Cell Renal Cell Carcinoma: Data on Tivozanib in Pretreated Patients
Thomas Powles, MD, on Clear Cell Kidney Cancer: Overall Survival Update With Adjuvant Pembrolizumab
Rohit K. Jain, MD, MPH, on Urothelial Carcinoma: New Data on Cabozantinib Plus Pembrolizumab
Andrea B. Apolo, MD, on Urothelial Carcinoma: Phase III Findings on Pembrolizumab vs Observation
2024 ASCO GI Cancers Symposium
Michael K. Gibson, MD, PhD, on Esophageal Cancer: Expert Commentary on Two Key Studies
Ken Kato, MD, PhD, on Advanced Esophageal Cancer: Biomarker Analyses From CheckMate 648
Ian Chau, MD, on Esophageal Squamous Cell Carcinoma: New Data on Nivolumab, Ipilimumab, and Chemotherapy
Manish A. Shah, MD, on Esophageal Cancer: Long-Term Outcomes of Pembrolizumab and Chemotherapy
Frank Kullmann, MD, on Metastatic Pancreatic Cancer: Recent Data on Gemcitabine and Nab-Paclitaxel
Anant Ramaswamy, DM, on Advanced Gastric Cancers: New Findings on Adding Docetaxel to Doublet
Van K. Morris, MD, on Colon Cancer: ctDNA as a Predictive Biomarker
Riccardo Lencioni, MD, on Hepatocellular Carcinoma: Transarterial Chemoembolization, Durvalumab, and Bevacizumab
Jennifer Yon-Li Wo, MD, on Colorectal and Pancreatic Cancers: New Findings on SBRT With Ipilimumab and Nivolumab
Lorraine A. Chantrill, PhD, MBBS, on Gastrointestinal Neuroendocrine Carcinomas: First-Line Treatment With Nab-Paclitaxel Plus Carboplatin
Milind M. Javle, MD, on Cholangiocarcinoma: New Data on Tinengotinib as Monotherapy
Yasunobu Ishizuka, MD, on Gastric Cancer: Does Nivolumab Infusion Time of Day Matter?
Dominik P. Modest, MD, on Colorectal Cancer: Health-Related Quality-of-Life Findings From CodeBreaK 300
Ian Chau, MD, on Gastrointestinal Cancers: Real-World Effectiveness of Nivolumab Plus Chemotherapy
Advertisement
Advertisement
Jan
05
Today In Oncology
Most Patients With Intermediate-Risk Breast Cancer May Safely Avoid Chest Wall Irradiation After Mastectomy
De-escalated Neoadjuvant Combination Therapy for HER2-Positive Early Breast Cancer
Learning From the ZEST Trial in Using ctDNA to Predict Breast Cancer Recurrence
Anthracyclines Plus Taxane-Based Chemotherapy for Certain Patients at High Risk for Breast Cancer Recurrence
BRCA-Mutation Carriers With Prior Diagnosis of Early-Onset Breast Cancer May Benefit From Risk-Reducing Surgery
View More
Advertisement